Drug For Life India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 4.28%
(FY 2023)
- Profit 3.59%
(FY 2023)
- Ebitda 45.57%
(FY 2023)
- Net Worth 30.33%
(FY 2023)
- Total Assets 18.98%
(FY 2023)
About Drug For Life India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Kumar and Navin Verma serve as directors at the Company.
- CIN/LLPIN
U24232CH2015PTC035515
- Company No.
035515
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Drug For Life India Private Limited offer?
Drug For Life India Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutritional Supplements, Pharma & Bioanalytical Services, PCD Pharma Franchise, Cardiovascular Drugs & Medication, Kidney Drugs, Common Disease Medicines, Injectable Products, Eye Drops, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Drug For Life India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navin Verma  | Director | 30-Apr-2015 | Current |
| Anil Kumar | Director | 30-Apr-2015 | Current |
Financial Performance of Drug For Life India.
Drug For Life India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.28% increase. The company also saw a slight improvement in profitability, with a 3.59% increase in profit. The company's net worth Soared by an impressive increase of 30.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Drug For Life India?
In 2023, Drug For Life India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Integrated Apparel Technology And Facilitation Centre Private LimitedActive 6 years 11 months
Navin Verma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Drug For Life India?
Unlock and access historical data on people associated with Drug For Life India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Drug For Life India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Drug For Life India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
